JP2016530323A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530323A5 JP2016530323A5 JP2016542315A JP2016542315A JP2016530323A5 JP 2016530323 A5 JP2016530323 A5 JP 2016530323A5 JP 2016542315 A JP2016542315 A JP 2016542315A JP 2016542315 A JP2016542315 A JP 2016542315A JP 2016530323 A5 JP2016530323 A5 JP 2016530323A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- tumor
- antigen
- administered
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361876509P | 2013-09-11 | 2013-09-11 | |
| US61/876,509 | 2013-09-11 | ||
| US201461971212P | 2014-03-27 | 2014-03-27 | |
| US61/971,212 | 2014-03-27 | ||
| US201461978401P | 2014-04-11 | 2014-04-11 | |
| US61/978,401 | 2014-04-11 | ||
| US201462003349P | 2014-05-27 | 2014-05-27 | |
| US62/003,349 | 2014-05-27 | ||
| PCT/EP2014/069425 WO2015036499A1 (en) | 2013-09-11 | 2014-09-11 | Anti-b7-h1 antibodies for treating tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019081639A Division JP2019163269A (ja) | 2013-09-11 | 2019-04-23 | 腫瘍を治療するための抗ｂ７−ｈ１抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016530323A JP2016530323A (ja) | 2016-09-29 |
| JP2016530323A5 true JP2016530323A5 (enExample) | 2017-10-12 |
| JP6550053B2 JP6550053B2 (ja) | 2019-07-24 |
Family
ID=51570487
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542315A Active JP6550053B2 (ja) | 2013-09-11 | 2014-09-11 | 腫瘍を治療するための抗ｂ７−ｈ１抗体 |
| JP2019081639A Pending JP2019163269A (ja) | 2013-09-11 | 2019-04-23 | 腫瘍を治療するための抗ｂ７−ｈ１抗体 |
| JP2020152079A Active JP7119037B2 (ja) | 2013-09-11 | 2020-09-10 | 腫瘍を治療するための抗ｂ７－ｈ１抗体 |
| JP2022021883A Active JP7342167B2 (ja) | 2013-09-11 | 2022-02-16 | 腫瘍を治療するための抗ｂ７－ｈ１抗体 |
| JP2023139429A Pending JP2023166474A (ja) | 2013-09-11 | 2023-08-30 | 腫瘍を治療するための抗ｂ７－ｈ１抗体 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019081639A Pending JP2019163269A (ja) | 2013-09-11 | 2019-04-23 | 腫瘍を治療するための抗ｂ７−ｈ１抗体 |
| JP2020152079A Active JP7119037B2 (ja) | 2013-09-11 | 2020-09-10 | 腫瘍を治療するための抗ｂ７－ｈ１抗体 |
| JP2022021883A Active JP7342167B2 (ja) | 2013-09-11 | 2022-02-16 | 腫瘍を治療するための抗ｂ７－ｈ１抗体 |
| JP2023139429A Pending JP2023166474A (ja) | 2013-09-11 | 2023-08-30 | 腫瘍を治療するための抗ｂ７－ｈ１抗体 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10336823B2 (enExample) |
| EP (2) | EP3656398A1 (enExample) |
| JP (5) | JP6550053B2 (enExample) |
| KR (5) | KR20240056664A (enExample) |
| CN (2) | CN105873606B (enExample) |
| AU (3) | AU2014320343B2 (enExample) |
| BR (1) | BR112016005303A2 (enExample) |
| CA (1) | CA2923499A1 (enExample) |
| DK (1) | DK3043816T3 (enExample) |
| ES (1) | ES2749744T3 (enExample) |
| HU (1) | HUE046674T2 (enExample) |
| IL (5) | IL292193B2 (enExample) |
| MX (1) | MX370818B (enExample) |
| NZ (2) | NZ757060A (enExample) |
| PL (1) | PL3043816T3 (enExample) |
| RU (1) | RU2701327C2 (enExample) |
| SA (1) | SA516370713B1 (enExample) |
| TW (1) | TWI643633B (enExample) |
| WO (1) | WO2015036499A1 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014151006A2 (en) | 2013-03-15 | 2014-09-25 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
| CN105873606B (zh) * | 2013-09-11 | 2020-12-29 | 米迪缪尼有限公司 | 用于治疗肿瘤的抗b7-h1抗体 |
| EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| CA2935423C (en) | 2014-01-24 | 2023-11-07 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
| AU2015210750B2 (en) | 2014-01-31 | 2020-08-20 | Children's Medical Center Corporation | Antibody molecules to TIM-3 and uses thereof |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| WO2015138920A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| DK3149042T3 (da) | 2014-05-29 | 2019-11-04 | Spring Bioscience Corp | PD-L1-antistoffer og anvendelser deraf |
| US20160031990A1 (en) * | 2014-05-29 | 2016-02-04 | Medlmmune, Llc | Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers |
| BR112017000497B1 (pt) | 2014-07-11 | 2023-12-26 | Ventana Medical Systems, Inc | Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1 |
| US20170275347A1 (en) * | 2014-09-05 | 2017-09-28 | Medimmune Limited | Methods for identifying patients responsive to anti-pd-l1 antibody therapy |
| WO2016040882A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of egfr inhibitors |
| WO2016061142A1 (en) | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| WO2016124558A1 (en) | 2015-02-03 | 2016-08-11 | Ventana Medical Systems, Inc. | Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1) |
| BR112017018234A2 (pt) | 2015-02-26 | 2018-04-17 | Merck Patent Gmbh | inibidores de pd-1 / pd-l1 para o tratamento de câncer |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| RU2017136709A (ru) * | 2015-04-23 | 2019-05-23 | Медиммьюн Лимитед | Комбинированное лечение немелкоклеточного рака легкого с выявленной мутацией в egfr |
| IL255312B (en) * | 2015-05-12 | 2022-08-01 | Genentech Inc | Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist |
| EP3307777A4 (en) | 2015-06-11 | 2019-02-13 | Wuxi Biologics (Shanghai) Co. Ltd. | NOVEL ANTI-PD-L1 ANTIBODIES |
| RU2766890C2 (ru) | 2015-06-16 | 2022-03-16 | Мерк Патент Гмбх | Комбинированные способы лечения антагонистами pd-l1 |
| EP4378957A3 (en) | 2015-07-29 | 2024-08-07 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| ES2878188T3 (es) | 2015-07-29 | 2021-11-18 | Novartis Ag | Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3 |
| WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| EP3389712B1 (en) | 2015-12-17 | 2024-04-10 | Novartis AG | Antibody molecules to pd-1 and uses thereof |
| CN106939047B (zh) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| WO2017176565A1 (en) | 2016-04-07 | 2017-10-12 | Eli Lilly And Company | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor |
| WO2017202744A1 (en) * | 2016-05-26 | 2017-11-30 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for cancer treatment |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| JP6910653B2 (ja) * | 2016-07-01 | 2021-07-28 | 国立大学法人東北大学 | 免疫チェックポイント阻害薬使用における免疫関連副作用の予測方法 |
| WO2018065938A1 (en) | 2016-10-06 | 2018-04-12 | Pfizer Inc. | Dosing regimen of avelumab for the treatment of cancer |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| EP3668876B1 (en) | 2017-08-18 | 2024-01-24 | Cothera Bioscience, Inc. | Polymorphic form of tg02 |
| WO2019152743A1 (en) * | 2018-01-31 | 2019-08-08 | Celgene Corporation | Combination therapy using adoptive cell therapy and checkpoint inhibitor |
| BR112020019116A2 (pt) * | 2018-03-22 | 2021-01-12 | Keires Ag | Proteínas de ligação, ácido nucleico, vetor, célula hospedeira, método de produção, proteína de ligação, composição farmacêutica e kit |
| BR112021014112A2 (pt) | 2019-01-18 | 2021-10-13 | Dracen Pharmaceuticals, Inc. | Usos de composto pró-fármaco de don e inibidor de ponto de controle imunológico para tratar câncer, bem como composto e composição farmacêutica compreendendo o mesmo |
| JP7582952B2 (ja) * | 2019-01-25 | 2024-11-13 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | 腫瘍治療用の併用医薬組成物 |
| AU2020248002A1 (en) | 2019-03-26 | 2021-10-21 | The Regents Of The University Of Michigan | Small molecule degraders of STAT3 |
| US12570679B2 (en) | 2019-03-29 | 2026-03-10 | Regents Of The University Of Michigan | STAT3 protein degraders |
| US20220265590A1 (en) | 2019-06-12 | 2022-08-25 | Vanderbilt University | Dibenzylamines as amino acid transport inhibitors |
| AU2020291464A1 (en) | 2019-06-12 | 2022-02-03 | Vanderbilt University | Amino acid transport inhibitors and the uses thereof |
| KR20220026575A (ko) * | 2019-06-25 | 2022-03-04 | 시티 오브 호프 | Pdl1 양성 nk 세포 암 치료 |
| BR112021026334A2 (pt) | 2019-06-27 | 2022-05-10 | Medstar Health | Macrófagos ativados por hdac6, composições, e usos dos mesmos |
| AU2020315401B2 (en) | 2019-07-16 | 2025-05-22 | The Regents Of The University Of Michigan | Imidazopyrimidines as EED inhibitors and the use thereof |
| US20220388978A1 (en) | 2019-08-27 | 2022-12-08 | Regents Of The University Of Michigan | Cereblon e3 ligase inhibitors |
| CN115023267A (zh) | 2019-09-19 | 2022-09-06 | 密歇根大学董事会 | 螺环雄激素受体蛋白质降解剂 |
| WO2021057836A1 (en) * | 2019-09-25 | 2021-04-01 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2021195481A1 (en) | 2020-03-26 | 2021-09-30 | The Regents Of The University Of Michigan | Small molecule stat protein degraders |
| US20230257365A1 (en) | 2020-07-10 | 2023-08-17 | The Regents Of The University Of Michigan | Small molecule androgen receptor protein degraders |
| US20230233690A1 (en) | 2020-07-10 | 2023-07-27 | The Regents Of The University Of Michigan | Androgen receptor protein degraders |
| CN116601140A (zh) | 2020-10-02 | 2023-08-15 | 羿尊生物医药股份有限公司 | 用于皮下施用的包含(s)-2-((s)-2-乙酰氨基-3-(1h-吲哚-3-基)丙酰氨基)-6-重氮基-5-氧代己酸异丙酯的冻干组合物及其用途 |
| US20240166647A1 (en) | 2021-03-03 | 2024-05-23 | The Regents Of The University Of Michigan | Cereblon Ligands |
| US20240190874A1 (en) | 2021-03-03 | 2024-06-13 | The Regents Of The University Of Michigan | Small molecule degraders of androgen receptor |
| TW202304458A (zh) * | 2021-03-26 | 2023-02-01 | 瑞典商阿斯特捷利康公司 | 用於黑色素瘤之組合治療 |
| CN120813375A (zh) | 2023-01-30 | 2025-10-17 | 凯玛布有限公司 | 抗体 |
| WO2025151487A2 (en) | 2024-01-08 | 2025-07-17 | Regents Of The University Of Michigan | Small-molecule inhibitors of adar1 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2192884C2 (ru) * | 2000-11-09 | 2002-11-20 | Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН | Вакцина для стимуляции противоопухолевого иммунитета |
| US7794710B2 (en) * | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| WO2009089149A1 (en) * | 2008-01-03 | 2009-07-16 | The Johns Hopkins University | B7-h1 (cd274) antagonists induce apoptosis of tumor cells |
| KR101050829B1 (ko) * | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| CN101693562A (zh) * | 2009-10-21 | 2010-04-14 | 山东大学 | 一种聚合氯化铁-聚环氧氯丙烷-二甲胺复合混凝剂 |
| NO2504364T3 (enExample) | 2009-11-24 | 2018-01-06 | ||
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| AU2013263076B2 (en) * | 2012-05-15 | 2017-08-31 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| CN105873606B (zh) * | 2013-09-11 | 2020-12-29 | 米迪缪尼有限公司 | 用于治疗肿瘤的抗b7-h1抗体 |
| EP3142751B1 (en) * | 2014-05-13 | 2019-08-07 | MedImmune Limited | Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer |
| US10092645B2 (en) * | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| US20170275347A1 (en) * | 2014-09-05 | 2017-09-28 | Medimmune Limited | Methods for identifying patients responsive to anti-pd-l1 antibody therapy |
| US20170320954A1 (en) * | 2014-11-17 | 2017-11-09 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| US20160347848A1 (en) * | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| BR112018071287A2 (pt) * | 2016-04-25 | 2019-02-19 | Medimmune, Llc | composições compreendendo coformulação de anticorpos anti-pd-l1 e anti-ctla-4 |
| CA3022636A1 (en) * | 2016-05-13 | 2017-11-16 | Medimmune, Llc | Cd40l-fc fusion polypeptides and methods of use thereof |
-
2014
- 2014-09-11 CN CN201480049982.1A patent/CN105873606B/zh active Active
- 2014-09-11 JP JP2016542315A patent/JP6550053B2/ja active Active
- 2014-09-11 CN CN202011433007.4A patent/CN112546217B/zh active Active
- 2014-09-11 TW TW103131437A patent/TWI643633B/zh active
- 2014-09-11 KR KR1020247013414A patent/KR20240056664A/ko not_active Ceased
- 2014-09-11 IL IL292193A patent/IL292193B2/en unknown
- 2014-09-11 AU AU2014320343A patent/AU2014320343B2/en active Active
- 2014-09-11 DK DK14766962.6T patent/DK3043816T3/da active
- 2014-09-11 IL IL313188A patent/IL313188B2/en unknown
- 2014-09-11 KR KR1020167007277A patent/KR102329584B1/ko active Active
- 2014-09-11 KR KR1020257042956A patent/KR20260008188A/ko active Pending
- 2014-09-11 KR KR1020227040760A patent/KR102661249B1/ko active Active
- 2014-09-11 RU RU2016113341A patent/RU2701327C2/ru active
- 2014-09-11 CA CA2923499A patent/CA2923499A1/en active Pending
- 2014-09-11 NZ NZ757060A patent/NZ757060A/en unknown
- 2014-09-11 KR KR1020217037457A patent/KR20210143932A/ko not_active Ceased
- 2014-09-11 MX MX2016002826A patent/MX370818B/es active IP Right Grant
- 2014-09-11 PL PL14766962T patent/PL3043816T3/pl unknown
- 2014-09-11 WO PCT/EP2014/069425 patent/WO2015036499A1/en not_active Ceased
- 2014-09-11 IL IL321966A patent/IL321966A/en unknown
- 2014-09-11 US US15/021,161 patent/US10336823B2/en active Active
- 2014-09-11 NZ NZ718821A patent/NZ718821A/en unknown
- 2014-09-11 ES ES14766962T patent/ES2749744T3/es active Active
- 2014-09-11 BR BR112016005303A patent/BR112016005303A2/pt not_active Application Discontinuation
- 2014-09-11 EP EP19191552.9A patent/EP3656398A1/en active Pending
- 2014-09-11 HU HUE14766962A patent/HUE046674T2/hu unknown
- 2014-09-11 EP EP14766962.6A patent/EP3043816B1/en active Active
-
2016
- 2016-03-03 IL IL244422A patent/IL244422B/en active IP Right Grant
- 2016-03-10 SA SA516370713A patent/SA516370713B1/ar unknown
-
2019
- 2019-04-23 JP JP2019081639A patent/JP2019163269A/ja active Pending
- 2019-05-21 US US16/418,488 patent/US10829557B2/en active Active
-
2020
- 2020-05-05 IL IL274462A patent/IL274462B/en unknown
- 2020-08-27 AU AU2020223728A patent/AU2020223728B2/en active Active
- 2020-09-10 JP JP2020152079A patent/JP7119037B2/ja active Active
- 2020-10-16 US US17/072,756 patent/US11827706B2/en active Active
-
2022
- 2022-02-16 JP JP2022021883A patent/JP7342167B2/ja active Active
-
2023
- 2023-08-30 JP JP2023139429A patent/JP2023166474A/ja active Pending
-
2024
- 2024-06-07 AU AU2024203898A patent/AU2024203898A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016113341A (ru) | Антитела к b7-h1 для лечения опухолей | |
| JP2016520082A5 (enExample) | ||
| Kordbacheh et al. | Current and emerging molecular therapies for head and neck squamous cell carcinoma | |
| JP2017537090A5 (enExample) | ||
| RU2016141385A (ru) | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf | |
| JP2022531408A5 (enExample) | ||
| Chami et al. | Radiation and immune checkpoint inhibitors: combination therapy for treatment of hepatocellular carcinoma | |
| JP2022501332A5 (enExample) | ||
| JP2008500964A5 (enExample) | ||
| JP2021511344A5 (enExample) | ||
| US9415078B2 (en) | Method of treating desmocollin-3 expressing cancer with Mycobacterium w | |
| WO2017176565A1 (en) | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor | |
| JP2018501247A5 (enExample) | ||
| Besse et al. | Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer (NSCLC) | |
| RU2812782C2 (ru) | Способ лечения острого миелоидного лейкоза | |
| RU2774721C2 (ru) | Применение комбинированного лечения на основе антитела к PD-1 и апатиниба для лечения трижды негативного рака молочной железы | |
| RU2023133857A (ru) | Антитела к b7-h1 для лечения опухолей | |
| WO2023185720A1 (zh) | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 | |
| Henry et al. | 325 MM-121 (SAR256212), an Anti-ErbB3 Monoclonal Antibody, Shows Synergistic Tumor Growth Inhibition in Combination with a Pan-PI3K Inhibitor or a Microtubule Inhibitor Through ErbB3 Expression Modulation | |
| CN120605267A (zh) | 双氢青蒿素在制备结直肠癌转移药物方面的应用 | |
| CN119212695A (zh) | 施用用于诱导肿瘤相关抗原的苔藓虫素的方法 | |
| Salnikov et al. | 322 Efficacy of Amanitin Conjugated Chimeric Anti-EpCAM Monoclonal Antibody in Experimental Carcinomas | |
| Grifantini et al. | 324 Monoclonal Antibodies Against Novel Tumor Markers for Diagnostic Prognostic and Predictive Applications | |
| Ciprotti et al. | 323 A Pilot Study of the Safety, Efficacy and Effects On Functional Imaging of the Combination of CG250 and Sunitinib in Patients (pts) with Advanced Renal Cell Carcinoma (RCC) | |
| RU2019129614A (ru) | Антитела к b7-h1 и к ctla-4 для лечения немелкоклеточного рака легкого |